Sickle Cell Disease: A Retrospective Chart Review

Novartis

Status: Completed

Conditions: Sickle Cell Anemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01441375

CICL670A2418

Details and patient eligibility

About

This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.

Enrollment: 261 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype
2. Patients ≥ 16 years of age
3. Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old
4. At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old

Exclusion criteria

1. Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period
2. Patients with sickle cell trait

Other protocol-defined inclusion/exclusion criteria may apply

Trial design

261 participants in 3 patient groups

Sickle cell patients non-transfused

Sickle cell patients transfused with no ICT

Sickle cell patients transfused with ICT